MOTS-c — Peptide Protocol Wiki reference

ty, and signaling remain to be fully characterized.

Long-term safety data are entirely absent.

MOTS-c: Mitochondrial Peptide Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

scade of metabolic changes including enhanced glucose uptake, increased fatty acid oxidation, inhibition of lipogenesis, and stimulation of mitochondrial biogenesis 1 .

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About MOTS-c 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides MOTS-c Mitochondrial & Cellular Energy Weight Loss & Metabolism preclinical MOTS-c Also known as: Mitochondrial Open Reading Frame of the 12S rRNA Type-c Compare with 2 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR MOTS-c is a 16-amino acid mitochondrial-derived peptide that activates AMPK signaling and functions as an exercise mimetic.

It regulates metabolic homeostasis, improves insulin sensitivity, and its circulating levels decline with age, positioning it as a candidate for metabolic disease and aging research.

Nuclear Translocation and Gene Regulation # A particularly notable feature of MOTS-c is its ability to translocate from mitochondria to the nucleus in response to metabolic stress.

Browse all mitochondrial peptides → Table of Contents 📌 TL;DR • Mitochondrial-derived peptide with metabolic regulatory functions • Enhances insulin sensitivity and glucose metabolism • Exercise mimetic properties in preclinical models • AMPK pathway activation for cellular energy regulation Community-Reported Side Effects Anecdotal ?

ol Quick-Reference Metabolic optimization, exercise mimetic effects, insulin sensitization, and anti-aging 💉 Dosing Amount 5-10 mg per injection Frequency 2-3 times per week or every 5 days Duration 4-6 weeks (20-day or 30-day protocols); repeat 2-4 times per year 💊 Administration Route SC Schedule 2-3 times per week or every 5 days Timing Morning or pre-exercise for metabolic activation ✓ Rotate injection sites 📅 Cycle Duration 4-6 weeks (20-day or 30-day protocols); repeat 2-4 times per year Repeatable Yes Course-based protocol with rest periods Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) Fasting glucose and HbA1c When: Baseline Why: Baseline glycemic status (MOTS-c improves insulin sensitivity) Fasting insulin When: Baseline Why: Baseline insulin resistance marker CMP When: Baseline Why: Baseline metabolic panel Lipid panel When: Baseline Why: Baseline lipid profile CRP When: Baseline Why: Baseline inflammation Fasting glucose and fasting insulin When: 4 weeks Why: Assess metabolic improvement 💡 Key Considerations → Contraindication: No formal contraindications established; use cautiously given complete absence of human safety data Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Peptide SS-31 mitochondrial-targeted antioxidant peptide Peptide Retatrutide triple-agonist metabolic peptide Peptide Cerebrolysin neuroprotective peptide mixture How MOTS-c works at the cellular level Overview of MOTS-c benefits and applications Scientific Details Molecular Formula C101H152N28O22S2 Molecular Weight 2174.6 Da CAS Number 1627580-64-6 Sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg What is MOTS-c?

MOTS-c belongs to a class of signaling molecules known as mitochondrial-derived peptides (MDPs), which are short open reading frames encoded within mitochondrial DNA that produce biologically active peptides.

MOTS-c has attracted considerable research interest due to its role as a retrograde signaling molecule, communicating metabolic information from mitochondria back to the nucleus.

This retrograde signaling function positions MOTS-c as a key mediator of mitochondrial-nuclear crosstalk, a process increasingly recognized as essential for metabolic homeostasis and cellular adaptation to stress.

Mechanism of Action # AMPK Pathway Activation # The primary molecular mechanism attributed to MOTS-c involves activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor.

MOTS-c activates AMPK through an indirect mechanism involving inhibition of the folate cycle and de novo purine biosynthesis pathway.

These findings were extended by subsequent studies showing that MOTS-c treatment increased physical performance in mouse models.

This mechanism provides a molecular explanation for the broad metabolic effects observed following MOTS-c administration in preclinical models and distinguishes MOTS-c from direct pharmacological AMPK activators such as metformin or AICAR itself, which act through different upstream mechanisms.

(2018; PMID 29983246) in Cell Metabolism demonstrated that under conditions of glucose restriction or oxidative stress, MOTS-c rapidly translocates to the nucleus where it interacts with chromatin and regulates the expression of nuclear genes involved in the antioxidant response and metabolic adaptation 2 .

In the nucleus, MOTS-c has been shown to promote the expression of genes containing antioxidant response elements (AREs), functioning similarly to the Nrf2 transcription factor pathway.

This nuclear activity represents a direct retrograde signaling mechanism by which a mitochondrial-encoded peptide can modulate nuclear gene expression in response to cellular stress conditions.

The nuclear translocation of MOTS-c is regulated by stress-induced post-translational modifications and appears to be a rapid

response mechanism, occurring within hours of stress exposure.

This positions MOTS-c as both a metabolic regulator and a stress-responsive signaling molecule.

Metabolic Regulation # MOTS-c exerts broad effects on metabolic homeostasis through multiple downstream pathways.

Activation of AMPK leads to increased translocation of glucose transporter type 4 (GLUT4) to the cell surface in skeletal muscle, enhancing insulin -independent glucose uptake.

Additionally, MOTS-c has been shown to promote fatty acid oxidation by phosphorylating and inactivating acetyl-CoA carboxylase (ACC), thereby reducing malonyl-CoA levels and relieving inhibition of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid import.

In adipose tissue, MOTS-c has been reported to promote browning of white adipocytes, increasing expression of uncoupling protein 1 (UCP1) and other thermogenic genes.

This browning effect may contribute to the observed increases in energy expenditure and resistance to diet-induced obesity in MOTS-c-treated animal models.

in Cell Metabolism (PMID 25738459) demonstrated that intraperitoneal administration of MOTS-c (5 mg/kg) to mice fed a high-fat diet prevented obesity and insulin resistance, mimicking key metabolic benefits of exercise without actual physical activity 1 .

MOTS-c-treated mice on a high-fat diet showed reduced body wei

ght gain, improved glucose tolerance, and enhanced insulin sensitivity compared to vehicle-treated controls 1 .

Aged mice treated with MOTS-c demonstrated improved treadmill running capacity and enhanced resistance to metabolic stress during exercise, supporting the characterization of MOTS-c as an exercise mimetic peptide.

The exercise-mimetic classification is based on MOTS-c's ability to reproduce several molecular signatures of exercise, including AMPK activation, enhanced mitochondrial biogenesis, increased fatty acid oxidation, and improved glucose disposal.

However, it is important to note that exercise produces a broader array of physiological adaptations that extend beyond metabolic changes, and MOTS-c does not replicate all benefits of physical activity.

(2021; PMID 33473109) 3 , MOTS-c treatment of aged mice (equivalent to approximately 65 human years) improved physical performance, restored metabolic parameters toward youthful levels, and enhanced skeletal muscle function.

Insulin Sensitivity and Diabetes Research # Preclinical studies have demonstrated that MOTS-c improves insulin sensitivity in models of diet-induced obesity and genetic obesity (Lee C et al.

Treatment with MOTS-c restores insulin signaling in skeletal muscle, reduces hepatic gluconeogenesis, and normalizes circulating glucose and insulin levels 1 .

In mouse models of type 2 diabetes, MOTS-c administration has been reported to reduce hemoglobin A1c levels and improve glucose disposal rates during insulin tolerance tests.

These findings have positioned MOTS-c as a candidate therapeutic for type 2 diabetes and metabolic syndrome, though no human clinical trials have yet been conducted to evaluate its efficacy in these conditions.

Treatment of aged mice with MOTS-c attenuated age-related loss of muscle mass (sarcopenia) and improved muscle strength as measured by grip strength